Vasamed, Inc. (VSMD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerVasamed, Inc. (VSMD) trades at $0.0001. Vasamed Incorporated designs, licenses, manufactures, and distributes products and software for assessing and managing hemodynamic health in the United States. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for VSMD: VSMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Vasamed, Inc. (VSMD) Healthcare & Pipeline Overview
Vasamed Incorporated specializes in hemodynamic health assessment, offering products like SensiLase PAD-IQ and Wound Imaging & SmartDraw systems for clinicians and patients in the U.S. The company, founded in 1988, focuses on diagnostic tools for vascular health, operating within the medical instruments and supplies sector from its Eden Prairie, Minnesota headquarters.
What Is the Investment Thesis for VSMD?
Vasamed Incorporated operates in the specialized medical instruments and supplies sector, focusing on hemodynamic health assessment and wound management with products like SensiLase PAD-IQ and Wound Imaging & SmartDraw systems. The company's established presence since 1988 and its targeted product portfolio addressing specific diagnostic needs for clinicians and patients in the U.S. represent its core value drivers. However, investors must consider the company's challenging financial profile, characterized by a reported market capitalization of $0.00B, a profit margin of -352.6%, and a gross margin of -5.0%. These metrics indicate significant operational losses and suggest that current revenues do not cover the cost of goods sold, let alone operating expenses. The negative beta of -1.02 also presents an unusual market correlation. Future growth catalysts would depend on achieving significant market penetration for its diagnostic systems, improving operational efficiency to reverse negative margins, and potentially securing strategic partnerships. The company's ability to navigate its current financial state and demonstrate a clear path to profitability will be paramount for any potential value creation, particularly given its 'OTC Other' market tier listing.
Based on FMP financials and quantitative analysis
VSMD Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or non-existent market valuation, reflecting significant financial challenges.
- Profit Margin: -352.6%, demonstrating substantial operational losses relative to revenue, highlighting profitability concerns.
- Gross Margin: -5.0%, suggesting that the cost of goods sold currently exceeds the revenue generated from product sales.
- Beta: -1.02, indicating an unusual inverse relationship with the broader market, which may imply unique market dynamics or low trading activity.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders, consistent with its current financial performance.
Who Are VSMD's Competitors?
VSMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GCTK GlucoTrack, Inc. | $1.11 | -8.26% | — | |
| LUCY Innovative Eyewear, Inc. | $0.89 | -0.21% | $5.61M | — |
| FEMY Femasys Inc. | $2.02 | -1.46% | $6.31M | — |
| RGNT Regentis Biomaterials Ltd. | $1.67 | -9.73% | $12.2M | 64 5-pillar |
| MLSS Milestone Scientific Inc. | $0.36 | -4.23% | $32.0M | — |
| HBIO Harvard Bioscience, Inc. | $8.50 | +1.92% | $38.3M | — |
| NEPH Nephros, Inc. | $3.55 | -3.27% | $39.4M | 33 5-pillar |
| POCI Precision Optics Corporation, Inc. | $4.46 | 0.00% | $48.7M | 37 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VSMD's Key Strengths?
Specialized product portfolio including SensiLase PAD-IQ and Wound Imaging & SmartDraw systems addressing specific diagnostic needs.
- Established operational history since 1988, suggesting experience and market understanding within the medical device sector.
- Integration of diagnostic hardware with software solutions like PAD-IQ Studycast enhances workflow efficiency for clinicians.
- Focus on hemodynamic health and wound care, serving critical areas within the U.S. healthcare market.
What Are VSMD's Weaknesses?
Significant financial underperformance, evidenced by a $0.00B market capitalization, -352.6% profit margin, and -5.0% gross margin.
- Operating on the 'OTC Other' market tier, which typically implies lower liquidity, less transparency, and higher investment risk.
- Unknown disclosure status on the OTC market, limiting public access to comprehensive financial and operational information.
- Negative beta of -1.02, indicating an unusual and potentially unpredictable market correlation.
What Are the Key Risks for VSMD?
Financial-distress signal — its Altman Z-Score of -48.35 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant financial losses, as evidenced by a -352.6% profit margin and -5.0% gross margin, pose a substantial threat to the company's long-term viability and ability to fund operations.
- Challenges associated with operating on the 'OTC Other' market tier, including extremely limited liquidity, unknown disclosure status, and potential difficulty in attracting institutional investment.
- Intense competition from larger, more financially robust medical device manufacturers with superior resources for research, development, and market penetration.
- Regulatory hurdles and compliance costs within the medical instruments and supplies industry could strain limited financial resources and delay product updates or market access.
- Dependence on the U.S. market for all operations and sales exposes the company to specific regional economic downturns or changes in U.S. healthcare policy.
What Threats Does VSMD Face?
- Intense competition from larger, well-capitalized medical device manufacturers with extensive R&D and marketing budgets.
- Ongoing regulatory challenges and compliance costs inherent in the medical instruments and supplies industry.
- Limited financial resources and sustained losses could hinder investment in R&D, marketing, and operational expansion.
- Market perception and investor confidence challenges due to its OTC status and current financial performance.
What Are VSMD's Competitive Advantages?
- Specialized Product Portfolio: Focus on niche areas of hemodynamic health assessment and wound measurement with proprietary systems like SensiLase PAD-IQ and Wound Imaging & SmartDraw.
- Established Presence: Founded in 1988, indicating a long operational history and experience within the medical device industry.
- Integrated Solutions: Offers both hardware (diagnostic devices) and software (PAD-IQ Studycast) components, providing a more comprehensive solution for users.
- Clinical Utility: Products designed to support specific diagnostic needs such as skin perfusion pressure and pulse volume recording, which are critical for managing vascular conditions.
What Does VSMD Do?
Vasamed Incorporated is a U.S.-based company established in 1988 and headquartered in Eden Prairie, Minnesota, dedicated to the design, licensing, manufacturing, and distribution of products, software, and services aimed at assessing and managing hemodynamic health. The company's core offerings address critical diagnostic needs for clinicians and patients, particularly in areas related to vascular health. A flagship product is the SensiLase PAD-IQ, a comprehensive system that supports various diagnostic measurements including skin perfusion pressure, pulse volume recording (PVR), and ankle brachial index (ABI) calculation using Doppler-obtained pressures. This system is crucial for the early detection and management of conditions like peripheral artery disease (PAD). Beyond vascular assessment, Vasamed also provides advanced solutions for wound care with its Wound Imaging & SmartDraw wound measurement systems. These systems are designed to offer precise and efficient wound assessment, which is vital for effective treatment planning and monitoring patient progress. Complementing its hardware, the company offers PAD-IQ Studycast, a software solution facilitating the rapid transmission of diagnostic test results to vascular specialists. This enables timely interpretation and the initiation of medically indicated therapeutic interventions, streamlining the diagnostic workflow. Additionally, Vasamed ensures the protection and portability of its equipment by offering custom carrying cases specifically designed for the PAD-IQ system. The company's focus remains on delivering specialized tools and services that enhance diagnostic capabilities and patient care within the hemodynamic health and wound management sectors across the United States.
What Products and Services Does VSMD Offer?
- Designs, licenses, manufactures, and distributes products for assessing hemodynamic health.
- Offers SensiLase PAD-IQ, a system for skin perfusion pressure, pulse volume recording, and ankle brachial index calculation.
- Provides Wound Imaging & SmartDraw systems for precise wound measurement.
- Develops PAD-IQ Studycast software for rapid transmission and interpretation of diagnostic tests by vascular specialists.
- Manufactures custom carrying cases for securing and protecting the PAD-IQ system.
- Serves clinicians and patients in the United States.
- Focuses on diagnostic tools and services within the medical instruments and supplies industry.
How Does VSMD Make Money?
- Generates revenue through the sale and licensing of specialized medical diagnostic devices, such as the SensiLase PAD-IQ system.
- Derives income from the distribution of wound measurement systems, including Wound Imaging & SmartDraw.
- Offers software-as-a-service (SaaS) or licensing for its PAD-IQ Studycast platform, facilitating remote diagnostic interpretation.
- Sells complementary accessories like custom carrying cases to enhance product utility and protection.
- Operates primarily within the United States, serving clinicians and patients directly or through distribution channels.
What Industry Does VSMD Operate In?
Vasamed Incorporated operates within the highly specialized and competitive medical instruments and supplies industry, specifically targeting the hemodynamic health and wound management segments in the United States. This sector is characterized by continuous innovation, stringent regulatory requirements, and a persistent demand for advanced diagnostic and monitoring tools. The market for hemodynamic assessment devices, driven by the increasing prevalence of cardiovascular diseases and conditions like peripheral artery disease (PAD), continues to grow. Similarly, the wound care market benefits from an aging population and rising incidence of chronic wounds, necessitating precise measurement and monitoring solutions. Vasamed's SensiLase PAD-IQ and Wound Imaging & SmartDraw systems position it within these niche markets, offering specialized diagnostic capabilities. While the overall industry benefits from stable demand, Vasamed faces competition from larger, more diversified medical device manufacturers with greater resources for R&D, marketing, and distribution. Its ability to carve out and maintain market share relies on the unique value proposition and clinical efficacy of its specialized products.
Who Are VSMD's Key Customers?
- Clinicians, including vascular specialists, podiatrists, and wound care professionals.
- Hospitals and medical centers requiring advanced diagnostic tools for hemodynamic health.
- Outpatient clinics and specialized diagnostic centers.
- Patients indirectly benefit from improved diagnostic accuracy and timely interventions facilitated by Vasamed's products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Vasamed, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Eden Prairie, US. The company is led by CEO Paulita LaPlante. VSMD has traded publicly since 1996.
Key Financial Metrics
Return on equity for Vasamed, Inc. stands at 315.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.98 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Vasamed, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.35 places it in the distress zone, a signal of elevated financial risk.
VSMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VSMD Latest News
No recent news available for VSMD.
VSMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VSMD.
Price Targets
Wall Street price target analysis for VSMD.
VSMD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VSMD; grades run from A+ (80-100) to F (below 30).
Leadership: Paulita LaPlante
CEO
Paulita LaPlante serves as the Chief Executive Officer of Vasamed, Inc. As CEO, she is responsible for overseeing the company's core functions, including product development, manufacturing, distribution, and financial management. Her tenure involves navigating the complexities of the medical instruments and supplies sector, focusing on hemodynamic health and wound management solutions.
Track Record: Under Paulita LaPlante's leadership, Vasamed, Inc. continues to design, license, manufacture, and distribute its specialized products and services, including the SensiLase PAD-IQ and Wound Imaging & SmartDraw systems. Specific achievements, strategic decisions, or company milestones directly attributable to her leadership are not detailed in the provided information. Her role involves guiding the company's efforts to serve clinicians and patients in the United States, focusing on the continued development and market presence of its diagnostic and wound measurement solutions.
VSMD OTC Market Information
Vasamed, Inc. trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have strict listing standards for financials, governance, and disclosures, the 'OTC Other' tier has minimal to no public reporting requirements. This often results in significantly less transparency for investors regarding a company's financial health and operations, distinguishing it from companies on higher OTC tiers or national exchanges that mandate regular, audited financial statements.
- OTC Tier: OTC Other
- Lack of Transparency: The 'Unknown' disclosure status on the 'OTC Other' tier means limited or no public financial reporting, making it difficult for investors to assess the company's true financial health and operational performance.
- Extremely Low Liquidity: Trading on the 'OTC Other' tier with a $0.00B market cap suggests very low trading volume and wide bid-ask spreads, making it challenging to buy or sell shares without significant price impact.
- Price Volatility: Due to low trading volume and limited information, the stock price can be highly volatile and susceptible to manipulation or significant swings based on minimal trading activity.
- Limited Access to Capital: Companies on lower OTC tiers often face greater difficulty in raising capital, which can constrain growth, product development, and operational stability.
- Regulatory Scrutiny: While disclosure requirements are minimal, companies on the 'OTC Other' tier may still face scrutiny from regulators regarding market integrity and investor protection.
- Verify any available financial statements, even if unaudited, to understand revenue, expenses, and cash flow.
- Research the background and track record of Paulita LaPlante and other key management personnel.
- Assess the market demand and competitive landscape for Vasamed's specific products (SensiLase PAD-IQ, Wound Imaging & SmartDraw).
- Investigate any regulatory approvals or certifications for its medical devices and software.
- Examine the company's legal and corporate structure, including any outstanding litigation or regulatory actions.
- Attempt to understand the company's operational footprint, manufacturing capabilities, and distribution network.
- Evaluate the company's capital structure and any potential need for future financing.
- Established Founding Date: Founded in 1988, indicating a long operational history, which can suggest a degree of stability.
- Specific Product Offerings: The company details specific products like SensiLase PAD-IQ and Wound Imaging & SmartDraw systems, suggesting tangible assets and operations.
- Physical Headquarters: Headquartered in Eden Prairie, Minnesota, providing a verifiable physical presence.
- Defined Business Focus: Clearly articulates its business in designing, licensing, manufacturing, and distributing products for hemodynamic health.
VSMD Healthcare Stock FAQ
What is the regulatory landscape for Vasamed, Inc.'s medical devices and software?
As a company operating in the medical instruments and supplies sector in the United States, Vasamed, Inc. is subject to the stringent regulatory oversight of the U.S. Food and Drug Administration (FDA).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Specific details for CEO Paulita LaPlante's background and track record are not provided in the source data, leading to general descriptions.